Baldwin Investment Management LLC Increases Stake in Edwards Lifesciences Corporation $EW

Baldwin Investment Management LLC boosted its stake in shares of Edwards Lifesciences Corporation (NYSE:EW) by 193.2% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 15,085 shares of the medical research company’s stock after purchasing an additional 9,940 shares during the period. Baldwin Investment Management LLC’s holdings in Edwards Lifesciences were worth $1,173,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of the stock. True Wealth Design LLC grew its holdings in shares of Edwards Lifesciences by 251.5% during the third quarter. True Wealth Design LLC now owns 362 shares of the medical research company’s stock valued at $28,000 after buying an additional 259 shares during the last quarter. NewSquare Capital LLC raised its stake in Edwards Lifesciences by 57.8% in the 2nd quarter. NewSquare Capital LLC now owns 366 shares of the medical research company’s stock worth $29,000 after acquiring an additional 134 shares during the last quarter. Rakuten Securities Inc. lifted its position in Edwards Lifesciences by 413.7% during the 2nd quarter. Rakuten Securities Inc. now owns 375 shares of the medical research company’s stock worth $29,000 after acquiring an additional 302 shares during the period. Hantz Financial Services Inc. lifted its position in Edwards Lifesciences by 76.6% during the 3rd quarter. Hantz Financial Services Inc. now owns 378 shares of the medical research company’s stock worth $29,000 after acquiring an additional 164 shares during the period. Finally, Steigerwald Gordon & Koch Inc. purchased a new stake in Edwards Lifesciences during the 3rd quarter valued at about $30,000. Institutional investors and hedge funds own 79.46% of the company’s stock.

Insider Activity

In other Edwards Lifesciences news, CFO Scott B. Ullem sold 7,700 shares of the stock in a transaction on Tuesday, December 9th. The shares were sold at an average price of $84.47, for a total transaction of $650,419.00. Following the transaction, the chief financial officer directly owned 39,898 shares of the company’s stock, valued at $3,370,184.06. This trade represents a 16.18% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, VP Daniel J. Lippis sold 1,019 shares of the business’s stock in a transaction dated Friday, January 9th. The stock was sold at an average price of $85.70, for a total transaction of $87,328.30. Following the sale, the vice president directly owned 22,002 shares of the company’s stock, valued at $1,885,571.40. This represents a 4.43% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 43,804 shares of company stock worth $3,699,082 over the last three months. 0.34% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on EW shares. The Goldman Sachs Group restated a “buy” rating and issued a $95.00 price objective (down from $108.00) on shares of Edwards Lifesciences in a research note on Wednesday, February 11th. Sanford C. Bernstein reissued a “market perform” rating and set a $90.00 price target on shares of Edwards Lifesciences in a research report on Monday, November 3rd. Wells Fargo & Company upped their price objective on shares of Edwards Lifesciences from $96.00 to $100.00 and gave the company an “overweight” rating in a report on Wednesday, February 11th. JPMorgan Chase & Co. raised shares of Edwards Lifesciences from a “neutral” rating to an “overweight” rating and raised their target price for the stock from $90.00 to $100.00 in a report on Thursday, December 18th. Finally, Canaccord Genuity Group set a $87.00 target price on shares of Edwards Lifesciences and gave the company a “hold” rating in a research report on Wednesday, December 17th. Three research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and nine have given a Hold rating to the company. According to data from MarketBeat, Edwards Lifesciences presently has a consensus rating of “Moderate Buy” and an average target price of $96.14.

Edwards Lifesciences Stock Performance

Shares of NYSE EW opened at $82.54 on Tuesday. Edwards Lifesciences Corporation has a 1 year low of $65.94 and a 1 year high of $87.89. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.29 and a current ratio of 4.00. The company’s fifty day moving average price is $82.79 and its 200 day moving average price is $81.08. The company has a market capitalization of $47.90 billion, a PE ratio of 45.11, a price-to-earnings-growth ratio of 2.08 and a beta of 0.94.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Tuesday, February 10th. The medical research company reported $0.58 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.62 by ($0.04). Edwards Lifesciences had a return on equity of 14.50% and a net margin of 17.69%.The firm had revenue of $1.57 billion for the quarter, compared to analysts’ expectations of $1.54 billion. During the same period in the previous year, the company earned $0.59 earnings per share. The company’s revenue was up 13.3% compared to the same quarter last year. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. On average, research analysts predict that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current year.

Edwards Lifesciences Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.